Regeneus Ltd.


Regeneus Ltd. is a clinical-stage regenerative medicine company developing a patented portfolio of therapies to address significant unmet medical needs in the human and veterinary health markets. The company has four therapies targeting human conditions in various stages of development including two products approved for first-in-human Phase 1 trials: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions; RGSH4K is a human autologous personalized therapeutic cancer vaccine to treat a wide range of cancer types. Furthermore, Regeneus is developing therapies to target acne and other inflammatory skin conditions in humans, in addition to musculoskeletal and oncology treatments for animals.